SCHEMBL6483883

SCHEMBL6483883

OC[C@@H](O)COc1cccc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 1.00
KDM4E B2RXH2 2/20 1.00
CYP2C19 P33261 2/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
NR2E1 Q9Y466 5/20 0.73
ADRB2 P07550 4/20 0.64
ADRB1 P08588 4/20 0.64
SIGMAR1 Q99720 4/20 0.64
CYP2D6 P10635 4/20 0.64
SLC6A4 P31645 3/20 0.64
HTR2B P41595 3/20 0.64
ALDH1A1 P00352 3/20 0.64
ADRB3 P13945 3/20 0.64
HTR2A P28223 3/20 0.64
HTR2C P28335 3/20 0.64
HTR6 P50406 3/20 0.64
LMNA P02545 3/20 0.64
SCN1A P35498 2/20 0.64
SLC10A1 Q14973 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483890 1.00 CYP1A2 (1.00) CYP1A2KDM4ECYP2C19MEN1KMT2A
SCHEMBL8566653 1.00 CYP1A2 (1.00) CYP1A2KDM4ECYP2C19MEN1KMT2A
SCHEMBL29437209 1.00 CYP1A2 (1.00) CYP1A2KDM4ECYP2C19MEN1KMT2A
SCHEMBL1394219 0.91 CYP1A2 (0.83) CYP1A2KDM4ECYP2C19MEN1KMT2A
SCHEMBL29437208 0.91 CYP1A2 (0.83) CYP1A2KDM4ECYP2C19MEN1KMT2A
SCHEMBL27902830 0.85 CYP1A2 (0.74) CYP1A2KDM4ECYP2C19MEN1KMT2A
SCHEMBL773269 0.85 NR2E1 (1.00) CYP1A2KDM4ECYP2C19MEN1KMT2A
SCHEMBL8539878 0.85 CYP1A2 (0.73) CYP1A2KDM4ECYP2C19MEN1KMT2A
SCHEMBL9777763 0.85 NR2E1 (1.00) CYP1A2KDM4ECYP2C19MEN1KMT2A
SCHEMBL9777869 0.85 NR2E1 (1.00) CYP1A2KDM4ECYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005003140-A1 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2005-01-13 WO disclosed
US-20050004161-A1 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents AGOURON PHARMACEUTICALS, INC. 2005-01-06 US disclosed
US-5208333-A (2R)-1-(ARYLOXY)-3-(BUTYRYLOXY)-2-PROPANOLS BASF AKTIENGESELLSCHAFT (DE) 1993-05-04 US disclosed
EP-0320726-A2 (2R)-aryloxyl-3-n-butyryloxy-propan-2-ols BASF Aktiengesellschaft (DE) 1989-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004161-A1 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents ZC3HAV1, IRF3, BRD4 CYP1A2 1382/4885KDM4E 40/4885CYP2C19 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.